The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > Physiogenex, Iris Pharma and CLEA Japan to present the features of diabetic retinopathy in the Uni-nephrectomized SDT fatty rat model at ARVO 2018, Honolulu, Hawaii

News detail

Return to all news & events

04/26/2018 Physiogenex, Iris Pharma and CLEA Japan to present the features of diabetic retinopathy in the Uni-nephrectomized SDT fatty rat model at ARVO 2018, Honolulu, Hawaii

Physiogenex, Iris Pharma and CLEA Japan will be presenting the features of diabetic retinopathy in the Uni-Nephrectomized SDT Fatty Rat, a novel Type 2 diabetic model of Diabetic Nephropathy, at the Association for Research in Vision and Ophtalmology 2018 conference (ARVO 2018) in Honolulu, Hawaii, USA.

Through their partnership, Physiogenex, Iris Pharma and CLEA Japan Inc., have developed and validated a novel rat model for evaluating drugs targeting diabetic retinopathy.

Within only 10 weeks, this obese and type 2 diabetic rat model, not only develops advanced kidney complications, but also features of diabetic retinopathy, that will be described in the poster presentation scheduled on May the 1st, 3:30pm to 5:15pm, poster#A0190, in the ARVO 2018 Exhibit Hall.

This study results will be presented by Dr. François Briand, Director of Research and Business Development at Physiogenex.

If you wish to know more about the SDT fatty rat model for setting-up a drug evaluation, ask Physiogenex experts:

https://www.physiogenex.com/contact-physiogenex-team/